R&D | April 17, 2026
Revvity aims to accelerate breakthroughs in cancer research
Revvity is positioning its technologies as a connected engine for discovery
Revvity is positioning its technologies as a connected engine for discovery
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Muted movement reflects consolidation phase as investors await earnings triggers
The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease
One Health-based surveillance model to focus on bird sanctuaries and high-risk human populations
ICMR-led consultation calls for stricter HFSS regulations, nutrition literacy, and healthier food environments
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The company reported net revenue of SEK 13.5 million for the full year 2025
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
Subscribe To Our Newsletter & Stay Updated
